Compare Adaptive Biotechnologies Corp (ADPT) vs Enphase Energy Inc (ENPH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Enphase Energy Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Enphase Energy Inc trades at $41.38 (market cap $5.67B). The key difference: Enphase Energy Inc is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | ENPH | |
|---|---|---|
Market Cap | $3.33B | $5.67B |
Sector | Health | Technology |
52-Week High | $22.37 | $72.33 |
52-Week Low | $10.24 | $26.12 |
Enterprise Value | $3.19B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ENPH trades at $42.99, down 0.19% on the day, with a bearish technical signal from moving averages. The company reported Q1 2026 EPS of $0.47, beating expectations, but revenue declined to $1.47B in 2025 from $2.3B in 2023. Recent news highlights its entry into AI data center power standards and new product launches, including IQ9N microinverters.
Outlook is mixed: analyst consensus is a 'Hold' with a $41.61 price target, below the current price. Opportunities include expansion into AI-driven energy solutions, but risks involve revenue volatility, high valuation multiples, and competitive pressures in the solar sector. Net cash flow remains positive but has weakened from prior years.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →
